Royal Bank of Canada Reiterates Outperform Rating for Insmed (NASDAQ:INSM)
Insmed (NASDAQ:INSM – Get Free Report)‘s stock had its “outperform” rating reiterated by equities researchers at Royal Bank of Canada in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $100.00 target price on the biopharmaceutical company’s stock. Royal Bank of Canada’s price target points to a potential upside […]
Insmed (NASDAQ:INSM – Get Free Report)‘s stock had its “outperform” rating reiterated by equities researchers at Royal Bank of Canada in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $100.00 target price on the biopharmaceutical company’s stock. Royal Bank of Canada’s price target points to a potential upside […]
